Cited 7 times in
Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박미숙 | - |
dc.contributor.author | 유형식 | - |
dc.contributor.author | 임준석 | - |
dc.contributor.author | 김기황 | - |
dc.contributor.author | 김명진 | - |
dc.date.accessioned | 2015-04-23T16:28:00Z | - |
dc.date.available | 2015-04-23T16:28:00Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0363-8715 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100634 | - |
dc.description.abstract | OBJECTIVE: To identify conditions that might impair the delayed selective hepatobiliary enhancement of gadobenate dimeglumine. MATERIALS AND METHODS: Ninety-five gadobenate-enhanced magnetic resonance imaging studies were retrospectively and independently analyzed. The effects of selective hepatic enhancement and biliary excretion were each categorized into 3 grades according to the perceived difference of signal intensity between the liver parenchyma and portal vein, and signal intensity in the common bile duct of precontrast- and delayed-phase images.History of diffuse liver disease, liver cirrhosis, and renal disease; elevated levels of blood urea nitrogen (BUN)/creatinine (Cr), aspartate aminotransferase (AST)/alanine aminotransferase, bilirubin, and alkaline phosphatase (ALP); ascites; and splenomegaly were compared according to the grade of hepatic and biliary enhancement. RESULTS: Diffuse liver disease (P = 0.002); cirrhosis (P < 0.001); renal disease (P = 0.022); ascites (P = 0.001); splenomegaly (P < 0.001); and elevated levels of BUN (P = 0.001), Cr (P = 0.003), AST (P < 0.001), bilirubin (P < 0.001), and ALP (P < 0.001) were factors that impaired selective hepatic enhancement. Biliary excretion was affected by the presence of liver disease (P < 0.001), cirrhosis (P < 0.001), splenomegaly (P < 0.001), ascites (P = 0.002), and elevated levels of Cr (P = 0.013), AST (<0.001), alanine aminotransferase (P = 0.001), bilirubin (P < 0.001), and ALP (P < 0.001). CONCLUSION: Delayed selective hepatobiliary enhancement of gadobenate dimeglumine can be impaired by liver or renal disease and/or by elevated levels of bilirubin, ALP, BUN, and Cr | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 113~120 | - |
dc.relation.isPartOf | JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Alanine Transaminase/blood | - |
dc.subject.MESH | Alkaline Phosphatase/blood | - |
dc.subject.MESH | Aspartate Aminotransferases/blood | - |
dc.subject.MESH | Biliary Tract/metabolism* | - |
dc.subject.MESH | Bilirubin/blood | - |
dc.subject.MESH | Blood Urea Nitrogen | - |
dc.subject.MESH | Contrast Media/pharmacokinetics* | - |
dc.subject.MESH | Creatinine/blood | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Image Enhancement/methods* | - |
dc.subject.MESH | Kidney Diseases/metabolism | - |
dc.subject.MESH | Liver/metabolism* | - |
dc.subject.MESH | Liver Diseases/metabolism | - |
dc.subject.MESH | Magnetic Resonance Imaging/methods* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Meglumine/analogs & derivatives* | - |
dc.subject.MESH | Meglumine/pharmacokinetics | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Observer Variation | - |
dc.subject.MESH | Organometallic Compounds/pharmacokinetics* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Splenomegaly/metabolism | - |
dc.title | Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiology (영상의학) | - |
dc.contributor.googleauthor | Honsoul Kim | - |
dc.contributor.googleauthor | Myeong-Jin Kim | - |
dc.contributor.googleauthor | Mi-Suk Park | - |
dc.contributor.googleauthor | Seung-Whan Cha | - |
dc.contributor.googleauthor | Joon Seok Lim | - |
dc.contributor.googleauthor | Hyung Sik Yoo | - |
dc.contributor.googleauthor | Ki Whang Kim | - |
dc.identifier.doi | 10.1097/RCT.0b013e3181aacd6b | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01463 | - |
dc.contributor.localId | A02533 | - |
dc.contributor.localId | A03408 | - |
dc.contributor.localId | A00345 | - |
dc.contributor.localId | A00426 | - |
dc.relation.journalcode | J01350 | - |
dc.identifier.eissn | 1532-3145 | - |
dc.identifier.pmid | 20118733 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00004728-201001000-00021&LSLINK=80&D=ovft | - |
dc.subject.keyword | magnetic resonance imaging | - |
dc.subject.keyword | gadobenate dimeglumine | - |
dc.subject.keyword | selective hepatic enhancement | - |
dc.subject.keyword | hepatobiliary enhancement | - |
dc.contributor.alternativeName | Park, Mi Sook | - |
dc.contributor.alternativeName | Yoo, Hyung Sik | - |
dc.contributor.alternativeName | Lim, Joon Seok | - |
dc.contributor.alternativeName | Kim, Ki Whang | - |
dc.contributor.alternativeName | Kim, Myeong Jin | - |
dc.contributor.affiliatedAuthor | Park, Mi-Suk | - |
dc.contributor.affiliatedAuthor | Yoo, Hyung Sik | - |
dc.contributor.affiliatedAuthor | Lim, Joon Seok | - |
dc.contributor.affiliatedAuthor | Kim, Ki Whang | - |
dc.contributor.affiliatedAuthor | Kim, Myeong Jin | - |
dc.citation.volume | 34 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 113 | - |
dc.citation.endPage | 120 | - |
dc.identifier.bibliographicCitation | JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, Vol.34(1) : 113-120, 2010 | - |
dc.identifier.rimsid | 37714 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.